Detalhe da pesquisa
1.
Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
BMC Cardiovasc Disord
; 23(1): 374, 2023 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37495953
2.
Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
J Cardiovasc Med (Hagerstown)
; 24(10): 758-764, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577867
3.
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
ESC Heart Fail
; 10(6): 3385-3397, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37670496
4.
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Eur J Health Econ
; 24(9): 1441-1454, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463524
5.
Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial.
PLoS One
; 12(9): e0184328, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949974